Yahoo
NYSE - Delayed Quote USD

Edwards Lifesciences Corporation (EW)

92.01 -2.43 (-2.57%)
At close: October 30 at 4:00:03 PM EDT
92.01 0.00 (0.00%)
After hours: October 30 at 6:00:01 PM EDT
Trade EW on Coinbase
Chart Range Bar
Loading chart for EW

What's happening with EW?

33m ago
Powered by Yahoo Scout

Edwards Lifesciences is approaching its November 4 Q3 earnings reportwith expectations for higher revenue and earnings. Recent FDA approvals expand its transcatheter valve portfolio, while a recall involving certain SAPIEN M3 delivery systems adds a safety and execution issue for investors to monitor.

Powered by Yahoo Scout
  • Previous Close 94.44
  • Open 94.55
  • Bid 91.64 x 10000
  • Ask 92.46 x 30000
  • Day's Range 91.87 - 95.34
  • 52 Week Range 74.66 - 96.29
  • Volume 6,044,548
  • Avg. Volume 3,337,221
  • Market Cap (intraday) 53.035B
  • Beta (5Y Monthly) 0.86
  • PE Ratio (TTM) 54.77
  • EPS (TTM) 1.68
  • Earnings Date Nov 4, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 101.87
  • Morningstar Rating Rating available with Stock Picks access

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

www.edwards.com

16,000

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

EW
7.93%
S&P 500 (^GSPC)
10.73%

1-Year Return

EW
10.22%
S&P 500 (^GSPC)
11.11%

3-Year Return

EW
47.55%
S&P 500 (^GSPC)
81.91%

5-Year Return

EW
23.21%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue 1.65B
Earnings 380.7M
Profit Margin 23.09%

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

0
500M
1B
2B
10.0%
15.0%
20.0%

Analyst Insights

View More

Analyst Price Targets

84.00 Low
101.87 Average
92.01 Current
117.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/7/2026
Analyst Barclays
Rating Action Initiated
Rating Overweight
Price Action Announces
Price Target 110

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    15.43%

  • Return on Assets (ttm)

    8.37%

  • Return on Equity (ttm)

    9.18%

  • Revenue (ttm)

    6.51B

  • Net Income Avi to Common (ttm)

    979.9M

  • Diluted EPS (ttm)

    1.68

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    4.25B

  • Total Debt/Equity (mrq)

    6.57%

  • Levered Free Cash Flow (ttm)

    1.23B

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: